Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 132

Results For "GE"

9985 News Found

Astellas, Seagen and Merck announce FDA acceptance of sBLA for PADCEV for urothelial cancer
Drug Approval | December 20, 2022

Astellas, Seagen and Merck announce FDA acceptance of sBLA for PADCEV for urothelial cancer

This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting


Aurigene reports results of AUR101 in phase II study in US patients
News | December 19, 2022

Aurigene reports results of AUR101 in phase II study in US patients

AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients


Torrent enters into co-marketing partnership with Boehringer Ingelheim India
News | December 15, 2022

Torrent enters into co-marketing partnership with Boehringer Ingelheim India

Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.


Hovione and GEA collaborate to advance continuous tableting
News | December 15, 2022

Hovione and GEA collaborate to advance continuous tableting

This partnership stemmed from a successful customer-supplier relationship spanning several years.


US Federal Court dismisses cancer linkage associated with Zantac
News | December 13, 2022

US Federal Court dismisses cancer linkage associated with Zantac

The current ruling will assure the safety of the use of Ranitidine for Indian patients


European Commission approves SPEVIGO for generalized pustular psoriasis flares
Drug Approval | December 13, 2022

European Commission approves SPEVIGO for generalized pustular psoriasis flares

EC grants conditional marketing authorization based on the EFFISAYIL trial


Lupin launches generic version of Pennsaid in the US
News | December 12, 2022

Lupin launches generic version of Pennsaid in the US

Diclofenac Sodium Topical Solution, 2% w/w (RLD PENNSAID) had estimated annual sales of US $509 million in the US (IQVIA MAT October 2022)


Roche presents new data for Polivy in previously untreated diffuse large B-cell lymphoma at ASH 2022
Clinical Trials | December 12, 2022

Roche presents new data for Polivy in previously untreated diffuse large B-cell lymphoma at ASH 2022

Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes


Emmes launches Cell and Gene Therapy Center
News | December 09, 2022

Emmes launches Cell and Gene Therapy Center

The new center will focus on supporting the clinical trials clients who are developing cell and gene therapies